Safety monitoring for GLP-1 therapy itself includes: Assessment for gastrointestinal adverse effects, which are common but usually transient Monitoring for signs of pancreatitis (severe, persistent abdominal pain) Vigilance for symptoms suggesting thyroid masses (neck lump, difficulty swallowing, persistent hoarseness) Regular review of glycaemic control in diabetic patients Blood pressure and cardiovascular risk factor assessment Monitoring for gallbladder disease (right upper abdominal pain, fever, jaundice) Eye examinations for people with diabetes, particularly those with pre-existing diabetic retinopathy Renal function checks, especially if experiencing severe gastrointestinal symptoms that could lead to dehydration If you have diabetes and take insulin or sulfonylureas, your doctor may reduce these doses when starting GLP-1 therapy to prevent hypoglycaemia
Dave Bischel, 52, of Sacramento, California, said he tasted something that reminded him of nickels after both of his Pfizer shots
However, the specific oral bioavailability percentage, the plasma concentration-time profile, and whether enteric coating meaningfully changes these parameters have not been published in human pharmacokinetic studies
If you or someone you love is navigating both weight challenges and alcohol use, you deserve care that sees the whole picture
Report Date: September 19, 2024
